More patients with estrogen receptor-positive, HER2-negative breast cancer treated with neoadjuvant endocrine therapy due to COVID-19
More patients with estrogen receptor-positive, HER2-negative breast cancer treated with neoadjuvant endocrine therapy due to COVID-19